ACE2 News and Research

RSS

More types of lung cells can be infected by SARS-CoV-2 than previously thought, scientists report

Scientists at Sanford Burnham Prebys, University of California San Diego and their international collaborators have reported that more types of lung cells can be infected by SARS-CoV-2 than previously thought, including those without known viral receptors.

23 Jul 2024

Understanding the new coronavirus mutant strain KP.3.1.1

Researchers in Japan evaluated the SARS-CoV-2 KP.3.1.1 variant, finding it has higher transmissibility and immune evasion compared to previous variants, posing new challenges for public health measures.

22 Jul 2024

High mutation count in new COVID-19 variants does not increase immune evasion, study finds

New research from UNC Charlotte's Center for Computational Intelligence to Predict Health and Environmental Risks (CIPHER) has found that the two recent and prevalent strains of the virus that cause COVID-19, SARS-CoV-2 variants BA.2.86 and JN.1, are not significantly better than their predecessor Omicron at evading immune responses and causing infections despite having a high number of mutations compared to Omicron.

19 Jul 2024

Mitochondrially-targeted antioxidants could reduce SARS-CoV-2 effects across multiple organs

Building upon groundbreaking research demonstrating how the SARS-CoV-2 virus disrupts mitochondrial function in multiple organs, researchers from Children's Hospital of Philadelphia (CHOP) demonstrated that mitochondrially-targeted antioxidants could reduce the effects of the virus while avoiding viral gene mutation resistance, a strategy that may be useful for treating other viruses.

15 Jul 2024

New host factors identified as important for SARS-CoV-2 infection

A research team led by Prof. Guo Yusong, Associate Professor of the Division of Life Science at the Hong Kong University of Science and Technology (HKUST), recently made a novel discovery related to the coronavirus (SARS-CoV-2) that causes COVID-19.

2 Jul 2024

At-home antibody tests could drive higher COVID-19 booster rates, new research finds

The feasibility and benefits of lateral flow assay (LFA)-based antibody tests for detecting inadequate COVID-19 immunity.

17 Jun 2024

Fertility warning: SARS-CoV-2 can linger in sperm for months after infection

Researchers at the University of São Paulo (USP) in Brazil have shown for the first time that SARS-CoV-2, the virus that causes COVID-19, can remain in the sperm of patients for up to 90 days after hospital discharge and up to 110 days after the initial infection, reducing semen quality.

4 Jun 2024

TMPRSS2 protein facilitates SARS-CoV-2 entry via unexpected pathway

How exactly do Sars-Cov-2 particles enter host cells? An international team led by Dr Richard Brown from Dr Daniel Todt's Computational Virology group at the Department of Molecular and Medical Virology at Ruhr University Bochum, Germany, together with researchers from the Paul-Ehrlich-Institut, investigated this question.

31 May 2024

COVID-19 associated with higher risk of erectile dysfunction

Men previously diagnosed with COVID-19 are at a greater risk of developing new-onset erectile dysfunction.

31 May 2024

COVID-19 virus can breach blood-retinal barrier, study finds

The blood-retinal barrier is designed to protect our vision from infections by preventing microbial pathogens from reaching the retina where they could trigger an inflammatory response with potential vision loss.

14 May 2024

Curcuminoid compounds show promise against COVID-19 in neuronal cells

The effects of curcumin and curcuminoids on a human neuroblastoma cell line (SH-SY5Y) infected with SARS-CoV-2.

14 May 2024

Novel bispecific antibodies show promise against evolving SARS-CoV-2 variants

Researchers developed bispecific antibodies targeting both the N-terminal and receptor binding domains of SARS-CoV-2, demonstrating significant neutralization across various Omicron variants, suggesting potential for new COVID-19 treatments.

9 May 2024

New SARS-CoV-2 KP.2 variant defies vaccines with higher spread, study warns

Study on the bioRxiv server reports that the SARS-CoV-2 KP.2 variant, despite lower infectivity, shows significant immune resistance and higher transmissibility compared to other variants, potentially impacting global public health and vaccine efficacy.

29 Apr 2024

Study suggests lingering coronavirus in tissues may contribute to long COVID symptoms

Study investigated whether SARS-CoV-2 lingers in tissues after COVID-19 recovery and if it's linked to long COVID symptoms. They found viral RNA in various organs, and its presence correlated with long COVID symptoms.

25 Apr 2024

New vaccine promises broad protection against SARS-CoV-2 and other sarbecoviruses

Researchers at Georgia Tech and the University of Wisconsin have created a broad-spectrum vaccine capable of defending against various SARS-CoV-2 variants and related bat coronaviruses.

17 Apr 2024

Study reveals how SARS-CoV-2 hijacks lung cells to drive COVID-19 severity

Researchers identified how SARS-CoV-2 targets and manipulates specific lung cells, using innovative techniques to trace the virus's impact on the cells' gene expression, revealing insights into early COVID-19 pathogenesis.

14 Apr 2024

Study reveals unexpected vulnerability of lung immune cells to SARS-CoV-2

The lung-cell type that's most susceptible to infection by SARS-CoV-2, the virus that causes COVID-19, is not the one previously assumed to be most vulnerable.

10 Apr 2024

Antibody discovery could explain mysteries about COVID-19 and long COVID

UVA Health researchers have discovered a potential explanation for some of the most perplexing mysteries of COVID-19 and long COVID.

28 Mar 2024

Heart at risk from ARDS: Inflammatory responses fuel cardiovascular complications

Research highlights the inflammatory impacts of ARDS on the heart, underscoring the role of immune responses in cardiovascular complications from viral infections, including COVID-19, and emphasizes the potential of TNF-α neutralizing therapy to mitigate these effects.

24 Mar 2024

Severity of current SARS-CoV-2 variants is not linked to the number of mutations

New research from UNC Charlotte's Center for Computational Intelligence to Predict Health and Environmental Risks (CIPHER) has found that the two most prevalent strains of the virus that cause COVID-19, SARS-CoV-2 variants BA.2.86 and JN.1, are not significantly better than their predecessor Omicron at evading immune responses and causing infections despite having a high number of mutations compared to previous variants.

19 Mar 2024